|
Roche’s Avastin Wins EU Approval for Recurrent Ovarian Cancer
The European Commission has approved Roche’s Avastin in combination with chemotherapy as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives